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A B S T R A C TObjective: To measure the clinical burden of invasive pneumococcal
disease (IPD) in selected developing countries. Methods: This is an
extensive literature review of published articles on IPD in selected
developing countries from East Asia, South Asia, Middle East, sub-
Saharan Africa, and Latin America. We reviewed all the articles
retrieved from the knowledge bases that were published between
the years 2000 and 2010. Results: After applying the inclusion,
exclusion, and quality criteria, the comprehensive review of the
literature yielded 10 articles with data for pneumococcal meningitis,
septicemia/bacteremia, and pneumonia. These selected articles were
from 10 developing countries from ﬁve different regions. Out of the 10
selected articles, 8 have a detailed discussion on IPD, one of them has
s detailed discussion on bacteremia and meningitis, and another one
has discussed pneumococcal bacteremia. Out of these 10 articles, onlysee front matter Copyright & 2013, International S
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r tunrazak, Cheras 56000, Kuala Lumpur, Malaysi5 articles discussed the case-fatality ratio (CFR). In our article review,
the incidence of IPD ranged from less than 5/100,000 to 416/100,000
population and the CFR ranged from 12.2% to 80% in the developing
countries. Conclusions: The review demonstrated that the clinical
burden of IPD was high in the developing countries. The incidence of
IPD and CFR varies from region to region and from country to country.
The IPD burden was highest in sub-Saharan African countries fol-
lowed by South Asian countries. The CFR was low in high-income
countries than in low-income countries.
Keywords: clinical burden, developing countries, East Asia, IPD, Latin
America, Middle East, South Asia, sub-Saharan Africa.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Streptococcus pneumoniae is a major public health problem causing
meningitis, bacteremia, pneumonia, and acute otitis media [1,2].
S. pneumoniae is the most common cause of pneumonia world-
wide, causing approximately 36% of all childhood pneumonias.
S. pneumoniae can cause potentially life-threatening lung infec-
tions including severe pneumonia, which hinders the movement
of oxygen into the bloodstream, potentially resulting in death
from respiratory failure [3]. Invasive pneumococcal infections
often prove rapidly fatal, even where good medical treatment is
readily available. In developed countries, up to 20% of people who
contract pneumococcal meningitis die; however, in the develop-
ing world, mortality is closer to 50%, even among hospitalized
patients [4]. In one study from Gambia, 48% of children who
contracted pneumococcal meningitis and reached hospital did
not survive [5]. The World Health Organization (WHO) estimated
that 1.6 million people die from pneumococcal disease every year
[6], with 0.7 million to 1 million being children younger than 5
years [7]. The pneumococcal disease burden among adults is alsohigh, with an estimated 600,000 to 800,000 adult deaths each year
from pneumococcal pneumonia, meningitis, and sepsis [8]. The
vast majority of its victims come from the world’s poorest
countries, and half of them are children younger than 5 years.
It is extraordinary, in view of these facts, that pneumococcal
disease remains a relatively unknown disease and does not have
a higher place on the agenda of the international community [3].
Compared with other diseases affecting the developing world,
determining the incidence of pneumococcal disease is relatively
difﬁcult [9]. This is due to a number of factors including the
difﬁculties involved in stringent laboratory testing and sample
collection and the unavailability of quality surveillance data in
developing countries. This lack of epidemiological evidence has
likely contributed to a gross underappreciation of the economic,
clinical, and human burdens imposed by pneumococcal disease
and hindered public health planning and decision making in
developing countries [3]. Most of the researchers have done the
review of invasive pneumococcal disease (IPD) for patients
belonging to a particular age group, for example, pediatric age
group, and limited to a single region. We extended our review ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 5 9 – 2 6 3260IPD to all age groups on the basis of availability of data and
extended to ﬁve different regions in the world. The developing
countries are deﬁned as a nation with a low living standard,
underdeveloped industrial base, and low human development
index relative to other countries [10]. This will help us better
understand the disease burden in all the age groups in selected
developing countries in different parts of the world. We meas-
ured the clinical burden of IPD in selected developing countries
by geographical and economical point of view. Clinical burden is
a burden that differs from genetic burden mainly in the added
component of morbidity; a trait that is either clinically or
genetically lethal may be grossly disabling [11].Methods
We conducted a detailed review of published articles on IPD.
Literature searches were conducted by using the PubMed data-
base, Google scholar, and The Lancet, and were limited to articles
written in English. We selected 10 developing countries from ﬁve
regions, namely, East Asia (Malaysia and Thailand), South Asia
(Bangladesh and Nepal), Middle East (Saudi Arabia and Qatar),
sub-Saharan Africa (The Gambia and Mozambique), and Latin
America (Cuba and Peru). The World Bank categorizes the
countries by income into ﬁve different categories: low-income
economics, lower-middle-income economics, upper-middle-
income economics, high-income economics, and high-income
Organisation for Economic Co-operation and Development mem-
bers [12]. The main criterion for the selection of these countries
from the designated regions was that they should belong to same
economic status (as deﬁned by the World Bank) and preferably be
neighbors. When selected countries did not have an equivalent
neighbor, we selected the next nearest country in the region with
the same economic status.
The search term combinations used to search the knowledge
base included pneumococcal pneumonia, epidemiology, inci-
dence rate, clinical burden AND pneumococcal meningitis, epi-
demiology, incidence rate, clinical burden AND pneumococcal
septicemia, epidemiology, incidence rate, and clinical burden. We
started with reviewing the abstracts of these articles published
between the year 2000 and 2010 to ﬁnd out which of the studies
met our inclusion criteria and then reviewed only those full-
length articles that complied with our inclusion criteria. The
knowledge base searches were conducted from March 1, 2011, till
July 31, 2011. We included only published articles and articles
that described the clinical burden of pneumococcal disease with51 were identifi
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Fig. 1 – Flow diagram for the process of review of the literature. *the quantitative data of the selected developing countries in the
different regions. If there was more than one article in each
country, the most comparable study or the study with a high
quality of methodology was reviewed. We excluded case reports,
reports, and special populations, such as reports for patients with
HIV/AIDS. We also excluded articles published before 2000 and
after 2010, or articles from developed countries. We accepted
each author’s deﬁnition and methods except for the exclusion
criteria mentioned.
Two individuals (Namaitijiang Maimaiti and Zafar Ahmed
[NM and ZA]) independently screened the titles and abstracts of
each citation retrieved from the search term and identiﬁed the
articles for full review. The decision to review an article in detail
was based on the content of the abstract and whether the article
described the clinical burden of pneumococcal disease. If the
reviewed article included both clinical and economic burdens of
pneumococcal disease, we still included this article in our study,
but reviewed only the clinical burden of disease for our study.
Initially, the search process using the search term yielded 51
articles. Finally, 22 articles remained to be reviewed in detail. If
more than one article from the same country was identiﬁed that
described the clinical burden of pneumococcal disease, we selected
the article with the later publication date with same quality or
better quality methods compared with previous studies. The
detailed review of the selected 22 articles was carried out by MN
and ZA in a team, and ﬁnally they selected 10 articles that fulﬁlled
all the selection criteria. Out of these 10 selected articles, 8 were
full-text original publications and 2 were review articles, and the 10
articles selected were then used for our analysis. We gathered
information such as study design (retrospective/prospective study),
study period, study location (urban/rural), study population and
age of sample, incidence rate, and case-fatality ratio (CFR) (Fig. 1).Results
The list of the selected articles from 10 developing countries
belonging to ﬁve different regions is presented in Table 1.
Among the 10 articles selected, 8 articles had a detailed
discussion on IPD, 1 discussed meningitis, and 1 discussed
pneumococcal bacteremia. Out of the 10 articles selected, only 5
articles described the CFR (Table 2). The studies included in this
review were carried out in a variety of settings. Seven studies
were carried out in an urban seating; two studies were carried out
in rural areas, whereas only one study was carried out in both
urban and rural settings.ed
9 from full text did not meet inclusion 
riteria, published before 2000 or after 2010, 
uplicate reference, repeated data or poor 
uality.
HI, high income; LI, low income; UMI, upper-middle income.
Table 1 – List of the 10 selected articles and data of publication.
No. Title of selected articles Year of
publication
Reference
1 Epidemiology of invasive pneumococcal infection in children aged ﬁve years and under in Saudi
Arabia: a ﬁve-year retrospective surveillance study
2010 [13]
2 Acute bacterial meningitis in Qatar 2006 [14]
3 Invasive pneumococcal disease among children in rural Bangladesh: results from a population-
based surveillance
2009 [15]
4 Invasive pneumococcal disease in Kanti Children’s Hospital, Nepal, as observed by the South
Asian Pneumococcal Alliance Network
2009 [16]
5 Invasive pneumococcal diseases among hospitalized children in Lima, Peru 2010 [17]
6 Bacterial meningitis in children and adolescents: an observational study based on the national
surveillance system
2005 [18]
7 Invasive pneumococcal disease in children o5 years of age in rural Mozambique 2006 [19]
8 Efﬁcacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive
pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
2006 [20]
9 Overview of the disease burden of invasive pneumococcal disease in Asia 2010 [21]
10 Incidence of pneumococcal bacteremia requiring hospitalization in rural Thailand 2009 [22]
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 5 9 – 2 6 3 261Table 3 shows that the IPD incidence ranged from less than 5
per 100,000 to 416 per 100,000. In general, the incidence rate of
IPD varies directly with the respective country’s income category,
with higher income countries having a low incidence rate and
low-income countries having a high incidence rate. The only
country that shows an exception is the Saudi Arabia, where the
overall incidence rate for IPD (bacteremia and meningitis) is 17.4
per 100,000 population; if we look at the incidence rate for
meningitis alone, 4/100,000, it is higher than that in Qatar, 2.4/
100,000.
Figure 2 also shows that the incidence rate in low-income
countries is way higher than the incidence rate in countries
among other income categories. We selected low-income coun-
tries from two different geographic regions. The data show that
the incidence rate of IPD in the low-income countries of sub-
Saharan Africa (Gambia and Mozambique) is considerably higher
than the incidence rate of IPD in the low-income countries from
South Asia (Bangladesh and Nepal).Table 2 – Summary of epidemiology of invasive pneumo












South Asia Bangladesh Low-income Population-based
surveillance
Nepal Low- income Retrospective stu
Middle east Saudi Arabia High- income Retrospective stu















CFR, case-fatality ratio; IPD, invasive pneumococcal disease; IR, incidencWhen we look at the incidence rate of IPD according to the
geographic region, we found that the incidence rate in East Asian
and Latin American countries was not very different from each
other—less than 10 per 100,000 for both the regions. The inci-
dence rate of IPD in middle eastern countries was slightly higher
than that in East Asian and Latin American countries, but it was
still less than 20 per 100,000.
Among the ﬁve regions, the CFR was reported in four regions
—East Asia, South Asia, Middle East, and Latin America. Based on
available data, the highest CFR was recorded in South Asia (80%),
followed by East Asia (33.3%), Latin America (27%), and Middle
East (12.2%). Concluding from these published evidences, we can
say that the incidence rate is high in low-income developing
countries such as Mozambique, Gambia, Bangladesh, and Nepal,
and this could be due to inequality, inequitable distribution of
wealth, inadequate provision of health care services, lack of
human resource and human capacity to manage IPD effectively,







2004–2006 Urban 216 o5 y
2005–2009 Rural 23,853 All age
groups
2004–2007 Rural 22,378 o5 y
dy 2004–2007 Urban 2,528 o5 y
dy 1999–2003 Urban 82 o5 y
dy 1998–2002 Urban 64 o12 y
2001–2003 Urban 10,702 o5 y
in a 2000–2003 Urban 17,437 o3 y
dy 2006–2008 Urban 101 o5 y
dy 1998–2003 Both 1,023 o18 y
e rate; PP, pneumococcal pneumonia.
Table 3 – The IR and CFR of pneumococcal disease by region, country, and economic level of countries
Region Country category Country IR of IPD/100,000 CFR
Middle east
High-income Saudi Arabia 17.4 12.20%
High-income Qatar 2.4 NA
East Asia
Upper-middle income Malaysia 8.6 33.30%
Upper-middle income Thailand 5.7 NA
Latin America
Upper-middle income Peru 7.7 22%
Upper-middle income Cuba 6 27%
South Asia
Low-income Bangladesh 86 NA
Low-income Nepal 52.4 80%
Sub-Saharan Africa
Low-income Mozambique 416 NA
Low-income Gambia 388 NA
CFR, case-fatality ratio; IPD, invasive pneumococcal disease; IR, incidence rate; NA, not applicable/available.
 Single disease IR.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 5 9 – 2 6 3262When we look at the CFR, it was high in low-income countries
(80%) and upper-middle-income countries (33.3%, 31.7%, and 22%)
than in high-income countries (12.2%). Even though the incidence
rate was higher in high-income countries than in upper-middle-
income countries, the CFR was low in these high-income coun-
tries than in middle-income countries. This can be explained
with the argument that generally high-income countries have
good capacity to provide excellent quality health care to their
population by using latest technology and hire properly qualiﬁed
professionals to operate health facilities.Discussion
The clinical burden of the disease was slightly different among
the neighboring countries within the same region in this review.
These differences in the disease burden between neighboring
countries even though they belong to the same economic level
may be due to differences in the health care system, human
resource, budget for health care expenditures, health insurance
coverage, climate, and so on. Collectively, these differences can
also be due to the objectives of the study, study design, different
sample demographic, location, and other factors. One of the
limitations of the study is that only two countries were selected
from each region.Fig. 2 – Incidence rate of IPD by income. IWe recommend that future studies should be carried out with
large sample size, be conducted in both urban and rural areas
among all age groups, and should report the CFR.
This study included ﬁve different regions covering both urban
and rural settings and critical morbidity. In this study, most of
the articles covered all age groups. A limitation of this study was
that it was conducted only in 10 developing countries and the
result may not reﬂect the situation in other developing countries.Conclusions
Our review conﬁrmed that the clinical burden of IPD was high in
developing countries. The incidence rate and the CFR of IPD were
different from region to region and country to country. The
disease burden was high in sub-Saharan African countries
followed by South Asian countries. The CFR was low in high-
income countries than in low-income countries. The disease
burden was not signiﬁcantly different among the countries that
belong to the category of upper-middle-income countries. The
review found that generally the disease burden was high in rural
areas than in urban areas, which can be explained by the inequity
in health care facilities available in rural areas. Studies from
Middle Eastern countries and Peru had a very small sample size;
therefore, because of the small sample size, these studies mayPD, invasive pneumococcal disease.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 5 9 – 2 6 3 263not reﬂect the true disease burden of these countries. Only three
studies were conducted among all age groups, and the other
studies were carried out only among children.
The WHO reported that 1.6 million people die every year
from pneumococcal disease, with 0.7 million to 1 million of
these being children younger than 5 years. The pneumococcal
disease burden among adults is also high, with an estimated
600, 000 to 800, 000 adult deaths each year from pneumococcal
pneumonia, meningitis, and sepsis [7]. The review done is in
accordance with the WHO report that says that the pneumo-
coccal disease burden is high among children as well as among
adult populations.
Source of ﬁnancial support: This research project was funded
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